1. Home
  2. EVO vs NEO Comparison

EVO vs NEO Comparison

Compare EVO & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.07

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo NeoGenomics Inc.

NEO

NeoGenomics Inc.

HOLD

Current Price

$10.60

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVO
NEO
Founded
1993
2001
Country
Germany
United States
Employees
4553
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
EVO
NEO
Price
$3.07
$10.60
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
8
Target Price
$7.00
$13.38
AVG Volume (30 Days)
47.1K
1.3M
Earning Date
04-08-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1.37
$10.63
Revenue Next Year
$10.05
$9.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$4.72
52 Week High
$4.42
$13.74

Technical Indicators

Market Signals
Indicator
EVO
NEO
Relative Strength Index (RSI) 56.03 74.64
Support Level $2.88 $9.35
Resistance Level $3.75 $10.66
Average True Range (ATR) 0.07 0.45
MACD 0.01 0.18
Stochastic Oscillator 89.58 95.96

Price Performance

Historical Comparison
EVO
NEO

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

About NEO NeoGenomics Inc.

NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Share on Social Networks: